Literature DB >> 23994273

Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia.

Athina Markou1, John D Salamone, Timothy J Bussey, Adam C Mar, Daniela Brunner, Gary Gilmour, Peter Balsam.   

Abstract

The present review article summarizes and expands upon the discussions that were initiated during a meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS; http://cntrics.ucdavis.edu) meeting. A major goal of the CNTRICS meeting was to identify experimental procedures and measures that can be used in laboratory animals to assess psychological constructs that are related to the psychopathology of schizophrenia. The issues discussed in this review reflect the deliberations of the Motivation Working Group of the CNTRICS meeting, which included most of the authors of this article as well as additional participants. After receiving task nominations from the general research community, this working group was asked to identify experimental procedures in laboratory animals that can assess aspects of reinforcement learning and motivation that may be relevant for research on the negative symptoms of schizophrenia, as well as other disorders characterized by deficits in reinforcement learning and motivation. The tasks described here that assess reinforcement learning are the Autoshaping Task, Probabilistic Reward Learning Tasks, and the Response Bias Probabilistic Reward Task. The tasks described here that assess motivation are Outcome Devaluation and Contingency Degradation Tasks and Effort-Based Tasks. In addition to describing such methods and procedures, the present article provides a working vocabulary for research and theory in this field, as well as an industry perspective about how such tasks may be used in drug discovery. It is hoped that this review can aid investigators who are conducting research in this complex area, promote translational studies by highlighting shared research goals and fostering a common vocabulary across basic and clinical fields, and facilitate the development of medications for the treatment of symptoms mediated by reinforcement learning and motivational deficits.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Learning; Motivation; Reinforcement; Reward

Mesh:

Year:  2013        PMID: 23994273      PMCID: PMC3849135          DOI: 10.1016/j.neubiorev.2013.08.007

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  219 in total

1.  Separate value comparison and learning mechanisms in macaque medial and lateral orbitofrontal cortex.

Authors:  M P Noonan; M E Walton; T E J Behrens; J Sallet; M J Buckley; M F S Rushworth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  The role of the dorsomedial striatum in instrumental conditioning.

Authors:  Henry H Yin; Sean B Ostlund; Barbara J Knowlton; Bernard W Balleine
Journal:  Eur J Neurosci       Date:  2005-07       Impact factor: 3.386

Review 3.  Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.

Authors:  John D Salamone
Journal:  IDrugs       Date:  2010-10

4.  Solving the credit assignment problem: explicit and implicit learning of action sequences with probabilistic outcomes.

Authors:  Wai-Tat Fu; John R Anderson
Journal:  Psychol Res       Date:  2007-04-20

Review 5.  Parallel incentive processing: an integrated view of amygdala function.

Authors:  Bernard W Balleine; Simon Killcross
Journal:  Trends Neurosci       Date:  2006-03-20       Impact factor: 13.837

6.  Deficits in sensory-specific devaluation task performance following genetic deletions of cannabinoid (CB1) receptor.

Authors:  Hans S Crombag; Alexander W Johnson; Anne M Zimmer; Andreas Zimmer; Peter C Holland
Journal:  Learn Mem       Date:  2009-12-24       Impact factor: 2.460

7.  Impairment of probabilistic reward-based learning in schizophrenia.

Authors:  Julia A Weiler; Christian Bellebaum; Martin Brüne; Georg Juckel; Irene Daum
Journal:  Neuropsychology       Date:  2009-09       Impact factor: 3.295

8.  Measuring extrastriatal dopamine release during a reward learning task.

Authors:  Elske Vrieze; Jenny Ceccarini; Diego A Pizzagalli; Guy Bormans; Mathieu Vandenbulcke; Koen Demyttenaere; Koen Van Laere; Stephan Claes
Journal:  Hum Brain Mapp       Date:  2011-11-23       Impact factor: 5.038

Review 9.  Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia.

Authors:  J S Yeomans
Journal:  Neuropsychopharmacology       Date:  1995-02       Impact factor: 7.853

10.  Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research.

Authors:  A Der-Avakian; M S D'Souza; D A Pizzagalli; A Markou
Journal:  Transl Psychiatry       Date:  2013-08-27       Impact factor: 6.222

View more
  44 in total

Review 1.  Translational Assessment of Reward and Motivational Deficits in Psychiatric Disorders.

Authors:  Andre Der-Avakian; Samuel A Barnes; Athina Markou; Diego A Pizzagalli
Journal:  Curr Top Behav Neurosci       Date:  2016

2.  Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.

Authors:  Samantha E Yohn; Daniela Alberati; Merce Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2017-01-12       Impact factor: 4.530

3.  GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders.

Authors:  Jared W Young; Mary E Kamenski; Kerin K Higa; Gregory A Light; Mark A Geyer; Xianjin Zhou
Journal:  Neuropsychopharmacology       Date:  2015-04-24       Impact factor: 7.853

4.  Clarifying the overlap between motivation and negative symptom measures in schizophrenia research: A meta-analysis.

Authors:  Lauren Luther; Melanie W Fischer; Ruth L Firmin; Michelle P Salyers
Journal:  Schizophr Res       Date:  2018-12-19       Impact factor: 4.939

5.  Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists.

Authors:  Marta Pardo; Laura López-Cruz; Noemí San Miguel; John D Salamone; Mercè Correa
Journal:  Psychopharmacology (Berl)       Date:  2015-02-03       Impact factor: 4.530

Review 6.  The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.

Authors:  M Hvoslef-Eide; A C Mar; S R O Nilsson; J Alsiö; C J Heath; L M Saksida; T W Robbins; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2015-07-24       Impact factor: 4.530

7.  The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia.

Authors:  Stéphane Raffard; Catherine Bortolon; Hanan Yazbek; Christophe Lançon; Michel Benoit; Joanna Norton; Delphine Capdevielle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-06-08       Impact factor: 5.270

8.  Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms.

Authors:  L Felice Reddy; William P Horan; Deanna M Barch; Robert W Buchanan; Eduardo Dunayevich; James M Gold; Naomi Lyons; Stephen R Marder; Michael T Treadway; Jonathan K Wynn; Jared W Young; Michael F Green
Journal:  Schizophr Bull       Date:  2015-07-03       Impact factor: 9.306

Review 9.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

Review 10.  Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.

Authors:  John D Salamone; Samantha E Yohn; Laura López-Cruz; Noemí San Miguel; Mercè Correa
Journal:  Brain       Date:  2016-05       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.